Novo Nordisk, a Danish pharmaceutical company, will launch a production facility for full-cycle manufacturing of insulin in Kaluga region.
This was announced by Hans Duijf, General Director of Novo Nordisk Russia/Belarus, at Pharmevolution 2018 forum held in Kaluga.
“In September, we will open a new shop to assemble multi-dose disposable injection pens, that is a modern form of insulin injection. The shop was built in 2017. Previously, these devices were not assembled in the Kaluga region. They will become available in the market at the end of 2018,” he said.
Novo Nordisk insulin plant was commissioned in the Kaluga region in 2015. Total investments in the regional production facility reached about 8 billion rubles.